Home
    Disclaimer
    ← Back to 5-MeO-MiPT
    5-MeO-MiPT molecular structure

    5-MeO-MiPT Stats & Data

    Psychedelic Empathogen Research-chemical
    Moxy 5meomipt 5meo-mipt
    NPS DataHub
    MW246.35
    FormulaC15H22N2O
    CAS96096-55-8
    IUPACN-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
    SMILESCOc1ccc2ncc(CCN(C)C(C)C)c2c1
    InChIKeyHEDOODBJFVUQMS-UHFFFAOYSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic
    Half-Life Unknown

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT1A receptor agonist
    5-HT2B receptor agonist
    5-HT2C receptor agonist
    Inhibitors
    Serotonin-norepinephrine reuptake inhibitor (SNRI, moderate potency)

    Receptor Binding

    norepinephrine reuptake inhibitor
    5-HT1A agonist

    History & Culture

    5-MeO-MiPT, commonly known as "Moxy," was first synthesized and characterized in 1985 when David Repke, Donald Grotjahn, and Alexander Shulgin published its synthesis and pharmacological profile in the Journal of Medicinal Chemistry. This publication represented the first known documentation of the compound, establishing that it had no prior history of human usage before this academic work. Shulgin later documented the substance more extensively in his influential book TiHKAL ("Tryptamines I Have Known and Loved"), which described its effects in humans and contributed to broader awareness within the psychedelic research community. Following its initial characterization, 5-MeO-MiPT remained relatively obscure until it began appearing as a novel designer drug around 2005. Since then, it has circulated primarily through the research chemical market rather than traditional street drug channels. The compound is used both recreationally and as an entheogen, typically obtained through online vendors operating in regulatory grey areas rather than through in-person distribution networks. Its presence in the research chemical market has continued for approximately two decades since its emergence into wider use.

    Subjective Effect Notes

    physical: The physical effects of 5-MeO-MiPT can be broken down into three components all of which progressively intensify proportional to dosage.

    cognitive: The head space of 5-MeO-MiPT is described by many as one which is both insightful and moderately relaxing, but at some points quite stimulating.

    Effect Profile

    Curated + 133 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10103.3
    Headspace Depth×3
    107.62.8
    Auditory Effects×1
    10101.4
    Body Load / Somatic Effects×1
    10103.6
    Catalog Erowid BlueLight
    Empathogen 10.0

    Strong empathy, euphoria, stimulation, and sensory enhancement

    Empathy / Social Openness×3
    106.72.1
    Euphoria / Mood Elevation×2
    109.08.9
    Stimulation×1
    107.59.3
    Sensory Enhancement×1
    10105.3
    Catalog Erowid BlueLight
    Based on reports from:
    Effect Index The Stillness and the Fluttering — nervewing TiHKAL TiHKAL #40: 5-MeO-MIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-MiPT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    19-40 minutes
    30 minutes - 1.0 hours
    2-3 hours
    2-3 hours
    2-4 hours
    Total: 5-8 hours
    Sublingual
    19 minutes - 1.0 hours
    30 minutes - 1.0 hours
    1-2 hours
    1-2 hours
    1-3 hours
    Total: 3-7 hours
    Smoked
    19 minutes - 1.0 hours
    1-4 minutes
    15-30 minutes
    1-2 hours
    1-2 hours
    Total: 5-8 hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown
    Addiction Potential
    Low; not typically habit-forming. Psychological compulsion is uncommon relative to stimulants or depressants.

    Tolerance Decay

    Full tolerance 0h Half tolerance 3d Baseline ~5d

    Based on Erowid’s basics page indicating a short tolerance window with near‑baseline by 5–7+ days; quantitative values are heuristic for planning gaps, not pharmacokinetic measurements. Cross‑tolerance pattern inferred from general psychedelic class behavior (TripSit).

    Cross-Tolerances

    LSD/psilocybin/other serotonergic psychedelics
    50% ●○○

    Experience Report Analysis

    Erowid BlueLight
    105 Reports
    2003–2025 Date Range
    78 With Age Data
    33 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 133 experience reports (105 Erowid + 28 Bluelight)

    133 Reports
    132 Effects Detected
    58 Positive
    50 Adverse
    24 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 58

    Music Enhancement 51.9% 88%
    Euphoria 51.9% 88%
    Stimulation 51.9% 84%
    Color Enhancement 45.8% 85%
    Tactile Enhancement 45.1% 86%
    Focus Enhancement 38.1% 70%
    Libido Enhancement 32.1% 84%
    Introspection 31.6% 80%
    Body High 30.8% 90%
    Geometric Imagery 28.6% 86%
    Joy 28.6% 84%
    Analysis Enhancement 28.6% 81%
    Empathy 28.5% 87%
    Sociability Enhancement 25.0% 82%
    Melting/flowing 21.4% 85%
    Patterning 21.4% 85%
    Morphing 21.4% 86%
    Contentment 21.4% 78%
    Entity Imagery 17.9% 80%
    Visual Trails 17.9% 78%

    Adverse Effects 50

    Anxiety 41.4% 79%
    Body Load 35.7% 82%
    Nausea 34.6% 84%
    Muscle Tension 32.3% 80%
    Confusion 22.5% 80%
    Fear 17.9% 83%
    Increased Heart Rate 16.2% 70%
    Social Anxiety 14.3% 79%
    Thought Disorganization 14.3% 79%
    Jaw Clenching 11.3% 80%
    Libido Suppression 10.7% 77%
    Paranoia 10.7% 82%
    Restlessness 10.7% 80%
    Memory Suppression 10.5% 80%
    Pupil Dilation 9.8% 89%
    Sweating 7.6% 70%
    Heaviness 7.1% 78%
    Stomach Cramps 7.1% 65%
    Delusion 7.1% 80%
    Emotional Lability 7.1% 80%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Light (n=18) Common (n=26)
    Visual Distortions 83.3% 92.3%
    Music Enhancement 77.8% 69.2%
    Stimulation 77.8% 53.8%
    Euphoria 66.7% 34.6%
    Anxiety 50.0% 65.4%
    Color Enhancement 44.4% 61.5%
    Muscle Tension 38.9% 61.5%
    Tactile Enhancement 55.6% 50.0%
    Focus Enhancement 50.0% 46.2%
    Sedation 50.0% 42.3%
    Empathy 38.9% 42.3%
    Auditory Effects 38.9% 42.3%
    Nausea 27.8% 42.3%
    Body High 38.9% 30.8%
    Closed-Eye Visuals 33.3% 38.5%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 105 experience reports.

    Limited tier coverage — most reports fall within the Light / Common range. Effects at other dose levels may not be represented.

    Oral dose range: 5.0–10.0 mg (median 8.0 mg)
    Effect Light (n=18) Common (n=26)
    visual distortions
    83%
    92%
    		→
    music enhancement
    78%
    69%
    		→
    stimulation
    78%
    54%
    		↓
    euphoria
    67%
    35%
    		↓
    anxiety
    50%
    65%
    		↑
    color enhancement
    44%
    62%
    		↑
    muscle tension
    39%
    62%
    		↑
    tactile enhancement
    56%
    50%
    		→
    focus enhancement
    50%
    46%
    		→
    sedation
    50%
    42%
    		↓
    empathy
    39%
    42%
    		→
    auditory effects
    39%
    42%
    		→
    nausea
    28%
    42%
    		↑
    body high
    39%
    31%
    		↓
    closed-eye visuals
    33%
    38%
    		↑
    jaw clenching
    28%
    		— →
    confusion
    22%
    27%
    		↑
    introspection
    17%
    27%
    		↑
    open-eye visuals
    11%
    23%
    		↑
    dissociation
    11%
    23%
    		↑

    Showing top 20 of 28 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers

    Light n=18
    10 positive 47.8% 9 adverse 24.7%
    Common n=26
    10 positive 42.7% 9 adverse 28.6%
    View effect breakdown

    Adverse Effects

    Effect Light (n=18) Common (n=26) Change
    Anxiety
    50%
    65%
    		+30%
    Muscle Tension
    39%
    62%
    		+58%
    Nausea
    28%
    42%
    		+52%
    Jaw Clenching
    28%
    		— 0%
    Confusion
    22%
    27%
    		+21%
    Increased Heart Rate
    22%
    15%
    		-30%
    Motor Impairment —
    15%
    		0%
    Pupil Dilation
    11%
    12%
    		3%
    Memory Suppression
    11%
    12%
    		3%
    Headache
    11%
    8%
    		-30%

    Positive Effects

    Effect Light (n=18) Common (n=26) Change
    Music Enhancement
    78%
    69%
    		-11%
    Stimulation
    78%
    54%
    		-30%
    Euphoria
    67%
    35%
    		-48%
    Color Enhancement
    44%
    62%
    		+38%
    Tactile Enhancement
    56%
    50%
    		-10%
    Focus Enhancement
    50%
    46%
    		-7%
    Empathy
    39%
    42%
    		8%
    Body High
    39%
    31%
    		-20%
    Introspection
    17%
    27%
    		+61%
    Creativity Enhancement
    11%
    12%
    		3%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 8.0 mg IQR: 5.0–10.0 mg n=53

    Real-World Dose Distribution

    62K Doses

    From 116 individual dose entries

    Smoked (n=8)

    Median: 10.0mg 25th: 8.0mg 75th: 17.5mg 90th: 26.5mg
    mg/kg median: 0.203 mg/kg 75th: 0.386

    Oral (n=86)

    Median: 7.35mg 25th: 5.0mg 75th: 10.0mg 90th: 17.75mg
    mg/kg median: 0.096 mg/kg 75th: 0.161

    Insufflated (n=5)

    Median: 10.0mg 25th: 1.0mg 75th: 20.0mg 90th: 23.0mg
    mg/kg median: 0.147 mg/kg 75th: 0.245

    Sublingual (n=8)

    Median: 6.5mg 25th: 4.75mg 75th: 12.5mg 90th: 20.0mg
    mg/kg median: 0.118 mg/kg 75th: 0.196

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.115 mg/kg IQR: 0.074–0.157 mg/kg n=53

    Redose Patterns

    Redosing behavior across 77 reports

    18.2% Redosed
    1.2 Avg Doses
    150m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Australia Potentially illegal (analogue) Could be treated as an illicit analogue under national drug legislation, though not explicitly scheduled.
    Austria Illegal (NPSG) Prohibited under the Neue Psychoaktive Substanzen Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal, though offenders with no intent to distribute may not face prosecution.
    Brazil Illegal Production, sale, and possession are prohibited under Portaria SVS/MS nº 344.
    Canada Unscheduled Not a scheduled substance, but illegal if sold for human consumption or recreational use.
    China Category I psychotropic substance Controlled as of September 2015. Illegal to sell, buy, import, export, and manufacture.
    Finland Illegal Banned in December 2014 as part of a government regulation prohibiting over 100 psychoactive chemicals from the consumer market.
    Germany Illegal (NpSG) Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to market, administration to others, marketing, and trading are punishable offenses. Possession is illegal but not subject to criminal penalties.
    Japan Designated Substance (Shitei-Yakubutsu) Controlled under the Pharmaceutical Affairs Law. Possession and sale are prohibited.
    Latvia Schedule I Classified as a Schedule I controlled substance under national drug legislation.
    Luxembourg Not prohibited Not listed among prohibited substances, making it technically legal though in a regulatory gray area.
    New Zealand Class C Treated as an analogue of DMT under the Misuse of Drugs Act, classifying it as a Class C controlled drug.
    Romania Illegal Prohibited along with other tryptamine derivatives as of January 2011.
    Switzerland Controlled (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E of Swiss drug regulations.
    Turkey Illegal Classified as a drug. Possession, production, supply, and import are prohibited.
    United Kingdom Class A Controlled under the Misuse of Drugs Act 1971 as an ether of 5-HO-MiPT, which falls under the tryptamine catch-all clause. Class A substances carry the most severe penalties.
    United States Unscheduled (Federal); Schedule I in some states Not scheduled at the federal level, but may be prosecuted under the Federal Analogue Act as an analog of 5-MeO-DiPT (Schedule I) if sold for human consumption. The DEA proposed scheduling in the 2020s but withdrew the proposal amid public opposition. Explicitly Schedule I in Florida, Louisiana (since June 2013), and Minnesota.

    Harm Reduction

    drugs.wiki

    • Potency varies widely; Erowid and TIHKAL document active effects in some people at 1–2 mg orally, while others need higher doses. Because 5‑MeO‑MiPT has a steep response curve and sub‑10 mg dosing, use a calibrated milligram scale and consider volumetric dosing to avoid accidental multi‑x overdoses. • Duration commonly spans 4–7 hours orally with an early body‑energized onset and residual stimulation that can delay sleep; some users report insomnia for several hours after baseline. Plan set/setting accordingly and avoid redosing to sleep. • Prominent body effects include anxious stimulation, muscle tension, tremor, and GI upset (gas/diarrhea/cramps); rare reports describe uncomfortable vasoconstriction—people with cardiovascular disease should be cautious and start low. Hydrate regularly, especially if dancing or in warm environments. • Interactions: combining with MAOIs can sharply increase serotonergic exposure (and caused strong potentiation with related tryptamines); avoid this combination. Stacking with stimulants or MDMA raises cardiovascular and anxiety risks; tramadol/DXM add serotonergic and seizure risk. If a calming agent is needed, use a single, known‑dose benzodiazepine cautiously and never with alcohol. • Identity/adulteration risks exist in the RC market; mislabeling as other compounds (e.g., stimulants) has been reported. Use reagent tests as a first pass (Ehrlich positive for indoles; Mecke/Mandelin often red‑brown/yellow‑brown for 5‑MeO tryptamines) and prioritize lab testing where available. Do not assume blotters/pills are correctly labeled. • Salt vs freebase: the HCl (or fumarate) salt is water‑soluble; freebase is poorly water‑soluble and intended for vaporization. If material won’t dissolve in water, it may be freebase or misidentified—do not force oral use; converting freebase to a salt requires proper acid/base handling. • Smoking/vaporizing uses larger masses than oral and produces an immediate rush followed by hours of trippiness; because data are limited and the inhaled route can feel more anxious/harsh, titrate very conservatively. Avoid open flame and overheating to limit degradation. • Tolerance rises acutely and typically diminishes over several days; spacing sessions by at least 5–7 days reduces attenuation and helps integration. Cross‑tolerance with classical psychedelics is likely. • Individuals with seizure histories, serious heart disease, or a family history of psychosis should be especially cautious; psychedelics can unmask latent vulnerabilities. Avoid driving or hazardous tasks during and after use due to impairments in attention, coordination, and visual processing. • Sexual/tactile enhancement is common but can encourage redosing; keep doses modest, maintain hydration/electrolytes, and communicate about consent as judgment can fluctuate under entactogenic effects.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to 5-MeO-MiPT